Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines

@article{Cleare2015EvidencebasedGF,
  title={Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines},
  author={Anthony J. Cleare and C. M. Pariante and A. H. Young and I. M. Anderson and David M. Christmas and P. J. Cowen and Chris Dickens and I. Nicol Ferrier and John R. Geddes and Simon Gilbody and P. M. Haddad and Cornelius L. E. Katona and G. Lewis and Andrea L. Malizia and RH McAllister-Williams and Paul G. Ramchandani and Jan Scott and D M Taylor and Rudolf Uher},
  journal={Journal of Psychopharmacology},
  year={2015},
  volume={29},
  pages={459 - 525}
}
A revision of the 2008 British Association for Psychopharmacology evidence-based guidelines for treating depressive disorders with antidepressants was undertaken in order to incorporate new evidence and to update the recommendations where appropriate. A consensus meeting involving experts in depressive disorders and their management was held in September 2012. Key areas in treating depression were reviewed and the strength of evidence and clinical implications were considered. The guidelines… 

Figures and Tables from this paper

Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology
TLDR
The British Association for Psychopharmacology guidelines specify the scope and targets of treatment for bipolar disorder, and recommend strategies for the use of medicines in short-term treatment of episodes, relapse prevention and stopping treatment.
Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology
TLDR
These updated guidelines from the British Association for Psychopharmacology replace the original version published in 2011 and address the scope and targets of pharmacological treatment for schizophrenia, including first-episode, relapse prevention, and illness that has proved refractory to standard treatment.
Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines
TLDR
There is a clear need for greater consistency across guidelines to ensure patients receive consistent evidence-based care, and this review provides a comprehensive overview of current pharmacological augmentation recommendations for major depression.
Antidepressants plus benzodiazepines for adults with major depression.
TLDR
Combined therapy of benzodiazepines plus antidepressants was more effective than antidepressants alone for depressive severity in the early phase (four weeks) and the primary outcome of acceptability, only overall dropout rates were available for all studies.
Pharmacological management of depressive disorders
Clinical guidelines for the management of treatment-resistant depression: French recommendations from experts, the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental
TLDR
The expert consensus guidelines will contribute to facilitate treatment decisions for clinicians involved in the daily assessment and management of treatment-resistant depression across a number of common and complex clinical situations.
Antidepressant pharmacotherapy in old-age depression—a review and clinical approach
TLDR
There is convincing evidence that antidepressants are efficacious in the treatment of old-age depression and that rationales are necessary for treatment planning, however, evidence-based data on recovery and remission rates in old- age depression specific to certain antidepressant drugs are still missing in trials.
A review of the management of antidepressant discontinuation symptoms
  • E. Wilson, M. Lader
  • Psychology, Medicine
    Therapeutic advances in psychopharmacology
  • 2015
TLDR
The available literature on the best methods of discontinuation for antidepressants in order to avoid or prevent the occurrence of any unpleasant side effects associated with antidepressant withdrawal is reviewed, highlighting the lack of controlled data to support the available guidelines.
Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders
TLDR
The Mood Disorder CPG is the first Clinical Practice Guideline to address both depressive and bipolar disorders and provides up-to-date recommendations and guidance within an evidence-based framework, supplemented by expert clinical consensus.
Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review
TLDR
Current major clinical practice guidelines provide little support for clinicians wishing to help patients discontinue or taper antidepressants in terms of mitigating and managing withdrawal symptoms, and the quality of the guidance was overall low.
...
...

References

SHOWING 1-10 OF 786 REFERENCES
Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines
TLDR
These guidelines cover the nature and detection of depressive disorders, acute treatment with antidepressant drugs, choice of drug versus alternative treatment, practical issues in prescribing and management, next-step treatment, relapse prevention, treatment of relapse, and stopping treatment.
Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines
TLDR
The guidelines cover the nature and detection of depressive disorders, acute treatment with antidepressant drugs, choice of drug versus alternative treatment, practical issues in prescribing, management when initial treatment fails, continuation treatment, maintenance treatment to prevent recurrence and stopping treatment.
Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology
TLDR
These British Association for Psychopharmacology guidelines cover the diagnosis of anxiety disorders and key steps in clinical management, including acute treatment, relapse prevention and approaches for patients who do not respond to first-line treatments.
Evidence-Based Guidelines for Treating Bipolar Disorder: Recommendations from the British Association for Psychopharmacology
  • G. Goodwin
  • Medicine, Psychology
    Journal of psychopharmacology
  • 2003
TLDR
The guidelines cover the diagnosis of bipolar disorder, clinical management and strategies for the use of medicines in short-term treatment of episodes, relapse prevention and stopping treatment.
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Drug treatment of depression: reflections on the evidence
TLDR
The thresholds of severity and, for milder depression, the duration of illness for which antidepressants are more effective than placebo; the next step in drug treatment when a patient has failed to respond adequately to a first antidepressant; and how long continuing on antidepressants should be recommended in relation to individual patients’ needs are examined.
Antidepressant drug effects and depression severity: a patient-level meta-analysis.
TLDR
The magnitude of benefit of antidepressant medication compared with placebo increases with severity of depression symptoms and may be minimal or nonexistent, on average, in patients with mild or moderate symptoms.
Combined pharmacotherapy and psychological treatment for depression: a systematic review.
BACKGROUND Adherence to antidepressant medication use is a problem in clinical practice. Some authors have posited that combined psychological treatment facilitates adherence to pharmacotherapy.
...
...